<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547339</url>
  </required_header>
  <id_info>
    <org_study_id>SCCC-0604122; STU 072010-019</org_study_id>
    <secondary_id>SCCC-062006-010</secondary_id>
    <secondary_id>CDR0000571546</secondary_id>
    <secondary_id>UMN-2006UC048</secondary_id>
    <nct_id>NCT00547339</nct_id>
    <nct_alias>NCT03554369</nct_alias>
  </id_info>
  <brief_title>Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase I and II Study of Stereotactic Body Radiation Therapy (SBRT) for Low and Intermediate Risk Prostate Cancer (SBRT Prostate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the&#xD;
      tumor and cause less damage to normal tissue.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of stereotactic&#xD;
      body radiation therapy and to see how well it works in treating patients with prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To escalate the dose of stereotactic body radiotherapy (SBRT) to a tumoricidal dose&#xD;
           without exceeding the maximum tolerated dose in patients with organ-confined prostate&#xD;
           cancer. (Phase I)&#xD;
&#xD;
        -  To determine the late, severe grade 3-5 genitourinary and gastrointestinal toxicity&#xD;
           occurring between 270-540 days (i.e., 9-18 months) from the start of the protocol&#xD;
           treatment as assessed by CTCAE v3.0. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine the dose-limiting toxicity of SBRT in these patients. (Phase I)&#xD;
&#xD;
        -  To determine the 2-year biochemical (PSA) control (freedom from PSA failure),&#xD;
           disease-free and overall survival, local control, freedom from distant metastases, and&#xD;
           the incidence of high-grade adverse events of any type in patients treated with this&#xD;
           therapy in order to determine if the therapy is promising enough for further clinical&#xD;
           investigation. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study followed by a phase II&#xD;
      open-label study.&#xD;
&#xD;
        -  Phase I: Patients undergo 5 treatments of stereotactic body radiotherapy (SBRT).&#xD;
&#xD;
        -  Phase II: Patients undergo SBRT at the maximum tolerated dose as in phase I. After&#xD;
           completion of study treatment, patients are followed at 1.5, 3, 6, 9, and 12 months,&#xD;
           every 6 months for 5 years, and then once a year for years 5-10.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 97 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Stage T1a, T1b, T1c disease&#xD;
&#xD;
               -  Stage T2a or T2b&#xD;
&#xD;
          -  No direct evidence of regional or distant metastases&#xD;
&#xD;
          -  No T2c, T3, or T4 tumors&#xD;
&#xD;
          -  Gleason score ≤ 7&#xD;
&#xD;
          -  Must meet the following criteria:&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) ≤ 20 ng/mL prior to starting hormonal therapy (if&#xD;
                  given) for patients with a Gleason score of 2-6&#xD;
&#xD;
               -  PSA ≤ 15 ng/mL prior to starting hormonal therapy (if given) for patients with a&#xD;
                  Gleason score of 7&#xD;
&#xD;
               -  Risk of pelvic lymph node involvement &lt; 20% according to Roach formula&#xD;
&#xD;
          -  Ultrasound-based volume estimation of the prostate gland ≤ 60 g&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior invasive malignancy, except for nonmelanoma skin cancer, unless disease-free&#xD;
             for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or&#xD;
             cervix are allowed)&#xD;
&#xD;
          -  No significant urinary obstructive symptoms&#xD;
&#xD;
               -  American Urological Association (AUA) score of ≤ 15 (alpha blockers allowed)&#xD;
&#xD;
          -  No history of inflammatory colitis (including Crohn disease and ulcerative colitis)&#xD;
&#xD;
          -  No history of significant psychiatric illness&#xD;
&#xD;
          -  No severe, active comorbidity including any of the following:&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the past 6 months&#xD;
&#xD;
               -  Transmural myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy within 30 days prior to&#xD;
                  registration&#xD;
&#xD;
               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects&#xD;
&#xD;
                    -  Laboratory tests for liver function and coagulation parameters are not&#xD;
                       required for entry into this protocol&#xD;
&#xD;
               -  AIDS (based on current CDC definition) or other immunocompromising condition&#xD;
&#xD;
                    -  HIV testing is not required for entry into this protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 9 months since prior hormonal therapy as neoadjuvant therapy or to downsize&#xD;
             the prostate gland&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No prior chemotherapy or surgery for prostate cancer&#xD;
&#xD;
          -  No prior transurethral resection of the prostate (TURP) or cryotherapy to the prostate&#xD;
&#xD;
          -  No plans for other concurrent post-treatment, adjuvant, antineoplastic therapy&#xD;
             including surgery, cryotherapy, conventionally fractionated radiotherapy, hormonal&#xD;
             therapy, or chemotherapy as part of the treatment for prostate cancer&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert D. Timmerman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Simmons Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

